Dextech Medical AB
DEXTECH.TE is a biotechnology company engaged in pharmaceuticals and medical research, primarily generating revenue through the development and commercialization of biotech products and services.
Business. DEXTECH.TE is a biotechnology and medical research company operating within the healthcare sector. The firm engages in pharmaceuticals and medical research activities, generating revenue through product sales. Specific details regarding its operating segments, headquarters location, and primary stock exchange listings are not available in the provided data. Consequently, the company is described at the industry level without further geographic or segmental breakdown.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
DEXTECH.TE is a biotechnology and medical research company operating within the healthcare sector. The firm engages in pharmaceuticals and medical research activities, generating revenue through product sales. Specific details regarding its operating segments, headquarters location, and primary stock exchange listings are not available in the provided data. Consequently, the company is described at the industry level without further geographic or segmental breakdown.
DEXTECH.TE exhibits a strong liquidity position, with a current ratio of 45.07, indicating that the company holds significantly more current assets than current liabilities. The company has no long-term debt and a debt-to-equity ratio of 0.0, suggesting a conservative capital structure with no leverage.
Profitability metrics for DEXTECH.TE are negative, with a return on equity (ROE) of -0.1956 and a return on assets (ROA) of -0.193. These figures indicate that the company is currently generating losses relative to its equity and asset base, which is below the typical performance of industry peers.
The company's revenue is reported as 0.0, and it has a negative gross profit of -651,890.0, operating income of -5,318,450.0, and net income of -4,844,700.0. These figures suggest that DEXTECH.TE is not currently generating positive earnings and is experiencing significant operational losses.
Geographically and segment-wise, the company's revenue concentration is not disclosed in the available data. However, the absence of segment-specific revenue data implies that the company may be operating in a single business line or has not disclosed its segmental performance.
Looking ahead, the company's growth trajectory is uncertain, as there are no disclosed revenue growth figures or outlooks for the current or next fiscal year. The company's capital expenditures of -3,223,020.0 indicate significant investment in infrastructure or R&D, but the lack of positive revenue growth suggests that these investments have not yet translated into earnings.
There are no immediate filing-based liquidity or dilution flags for DEXTECH.TE. The company has a low dilution risk, with no near-term pressure for additional share issuance. The absence of dilution risk is supported by the fact that the company has not issued additional shares in the recent period.
- DEXTECH.TE has a strong liquidity position with a current ratio of 45.07 and no long-term debt.
- The company is currently unprofitable, with a negative ROE of -0.1956 and ROA of -0.193.
- DEXTECH.TE is not generating positive revenue and is experiencing significant operational losses.
- The company has a low dilution risk, with no immediate filing-based liquidity or dilution flags.
- The company's growth trajectory is uncertain, with no disclosed revenue growth figures for the current or next fiscal year.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Return On Assetsnet_income / total_assets
- DEXTECH.TE Market data — financials · 2026-05-27